Academic literature on the topic 'Hormon rasta'

Introduction/Aim: Spondylodysplastic Ehlers-Danlos Syndrome (sdEDS) is a rare genetic disorder of collagen synthesis, caused by a mutation in the B4GALT7, B3GALT6, or SLC39A13 gene. Features of this very rare disorder are short stature, hypotonia, hyperflexible joints, soft, thin, and overly stretchable skin, sparse hair and eyebrows, elderly face, wide forehead and prolonged wound healing. Molecular genetic analysis is needed for definite confirmation of the diagnosis. So far, only three case reports describing growth hormone treatment response in patients with sdEDS have been published. All of these patients had growth hormone (GH) deficiency. We present the first case report regarding growth hormone treatment response in a patient with sdEDS and normal GH secretion (without GH deficiency). Case report: Patient was a girl with short stature and normal GH secretion. Having in mind that the girl was born small for the gestational age, due to her short stature, she started using HR, before the diagnosis of sdEDS was made. Based on the lack of improvement in growth velocity as well as the girl's phenotype, genetic analyses were performed and the diagnosis of sdEDS due to biallelic mutations of the B4GALT7 gene was established. After the diagnosis of sdEDS was made and due to suboptimal response in growth velocity to the GH treatment, the GH therapy was stopped at the age of 11 years. Conclusion: This is a first case report regarding GH treatment in a child with sdEDS and normal GH secretion, demonstrating a very limited therapeutic effect of GH on linear growth in the presented patient.

Tyrimo tikslas. Ištirti p53 baltymo ir HER2 (c-erbB-2) receptorių padidėjusios raiškos įtaką II stadijos krūties vėžiu sirgusių jaunų moterų penkerių metų išgyvenamumui, atsižvelgiant į hormonų receptorių bei gydymo savitumų reikšmę. Tyrimo medžiaga ir metodai. Retrospektyviai analizuojama 34 Kauno apskrities moterų, gydytų 2001–2003 m. Kauno onkologijos ligoninėje, medicininė dokumentacija ir archyvinė histologinė medžiaga. Tiriamųjų kontingentas – jaunos, iki 50 metų moterys, kurioms diagnozuotas ir morfologiškai patvirtintas II stadijos krūties vėžys. 22 moterys išgyveno penkerius metus, 12 mirė penkerių metų laikotarpiu. Panaudojant archyvinę histologinę medžiagą de novo, tuometinėje KMUK Patologinės anatomijos klinikoje buvo atliktas p53 baltymo ir HER2 receptorių raiškos tyrimas imunohistocheminiu metodu. Panaudojant medicininę dokumentaciją, analizuota pacientėms skirta adjuvantinė chemoterapija, antraciklinų suminė dozė ir hormoninis gydymas. Rezultatai. Tarp visų 34 tiriamųjų 20,6 proc. atvejų rasta padidėjusi p53 baltymo raiška, 26,4 proc. atvejų – HER2 baltymo raiška. Analizuojant išgyvenamumą Kaplan-Meier metodu, nustatyta, kad mirties tikimybė penkerių metų laikotarpiu didesnė, kai naviko histologinėje medžiagoje rastas padidėjęs p53 baltymo kaupimasis, neigiami estrogenų receptoriai ir kai pacientės gydytos nepakankama antraciklino doze (log rank p=0,013, log rank p=0,02, log rank p=0,027, atitinkamai). Nerasta sąsajų tarp padidėjusios HER2 baltymo raiškos ir pacienčių penkerių metų išgyvenimo (log rank p=0,51). Daugiamatės analizės metodu nustatyta, kad vienintelis nepriklausomas veiksnys yra nepakankama antraciklinų dozė (p=0,028). Išvada. Jaunų moterų, susirgusių II stadijos krūties vėžiu, trumpesnei gyvenimo trukmei įtakos turi padidėjusi p53 baltymo raiška, sumažinta antraciklinų dozė ir neigiami estrogenų receptoriai, o HER2 baltymo padidėjusios raiškos įtakos penkerių metų gyvenimo trukmei nepavyko įrodyti. Nepriklausomas prognozinis veiksnys yra nepakankamas adjuvantinis gydymas antraciklinais.

The objective of the present study was to evaluate the efficacy and safety of the application of the new soluble pharmaceutical form of Rastan for subcutaneous injections at a dose of 15 IU/ml and compare its action with that of Rastan lyophilisate, 4 IU, designed to prepare solutions for subcutaneous administration. The two dosage forms are used to treat children suffering from growth hormone deficiency. The study included patients at the age from 4 to 12 years presenting with idiopathic growth hormone deficiency; they were randomized into two groups. During the first three months, the patients of both groups were treated with different pharmaceutical forms of recombinant growth hormone (rGH). The children in group 1 were given Rastan for subcutaneous injections and those in group 2 received Rastan lyophilysate for the preparation of solutions for the subcutaneous administration. Either form of GH was used at an equal daily dose of 0.033 mg/kg b.w. The patients of both groups showed marked improvement of the parameters of linear growth within the first three months. The difference in the growth rates was not significantly different between the two groups which suggests the identical effect of the two forms of rGH. During the next 9 months when the patients of both groups were treated only with the rGH for subcutaneous injections, the absolute growth response, height SDS, and the level of insulin-like growth factor 1 (IGF-1) continued to increase. It points out to the stable growth-promoting effect of Rastan for subcutaneous injections. No clinically significant abnormal changes in the results of complete blood cell count and biochemical analysis of blood were apparent during 12 months of therapy with this form of rGH. The same was true of the levels of free T4, cortisol, and prolactin in the blood. No adverse effects attributable to the therapy with rGH were documented.

Fiziološke koncentracije spolnih hormona 17β-estradiola i testosterona varijaju s obzirom na vrstu životinje, dob, spol, pasminu, način držanja, hranidbu, stres i okolišne čimbenike. Navedeni hormoni su nužni za rast i razvoj životinje te njihovu spolnu zrelost i reproduktivnu funkciju. Zbog svog anaboličkog učinka koristili su se u prošlosti u intenzivnoj stočarskoj proizvodnji kao promotori rasta, putem stočne hrane ili u obliku implatanta. No, zbog svojih toksičnih učinaka u životinja i ljudi, uključujući mutagenost, kancerogenost i teratogenost, njihova je uporaba zabranjena u svrhu proizvodnje hrane životinjskog podrijetla. Danas je dopušteno korištenje prirodnih hormona samo u terapeutske svrhe za liječenje poremećaja reprodukcije i gravidnosti. S obzirom na stalni razvoj novih sintetskih tvari koje bi mogle imati anabolički učinak i mogu zlouporabu, nužno je tijekom redovitog provođenja kontrole te poznavanja fizioloških vrijednosti razina ovih hormona. Cilj ovog rada, uzimajući u obzir sve navedeno, bilo je istražiti razine prirodnih hormona 17β-estradiola i testosterona u krvi teladi različitog spola, pasmina, dobi i farmskog podrijetla na području Republike Hrvatske. U tu svrhu s tri različite farme na području Republike Hrvatske nasumično su izabrana 32 teleta različitog spola (5 muških i 27 ženskih), dobi 2 ‒ 5 mjeseci starosti, različitih pasmina i kategorija (13 teladi simentalske pasmine, 2 teladi mesne pasmine, 17 teladi holštajnske pasmine). Prilikom općeg kliničkog pregleda životinje od strane nadležnog veterinara, nisu primijećeni nikakvi znaci bolesti ili stanja koje bi mogle utjecati na razine ovih hormona. Prosječna razina 17β-estradiola iznosila je 28,8±11,0 ng/L. Koncentracija testosterona bila je niža od limita detekcije primjenjene analitičke metode u 24 uzorka plazme teladi, a detektirana je u 8 uzoraka s prosječnom koncentracijom od 126,7±167,5 ng/L, ukazujući na široku varijabilnost u koncentracijama ovog hormona. Statistički značajna razlika u koncentracijama određena je jedino za 17β-estradiol s obzirom na pasminski sastav i farmu podrijetla (P<0,05). S obzirom da su ustvrđene koncentracije u skladu s fiziološkim razinama iz ranije provedenih istraživanja u literaturi, u pretraživane teladi se može isključiti sumnja na ilegalnu uporabu sredstava s anaboličkim učinkom.Ključne riječi

Persalinan yang nyaman merupakan dambaan setiap ibu yang ingin melahirkan. Tubuh ibu yang menjalani persalinan dengan perasaan nyaman akan mengeluarkan endorpin. Endorpin merupakan hormon penghilang rasa sakit alami yang dipercayai oleh para ahli memiliki 200 kali efek yang lebih kuat dari morfin. Banyak metode yang dapat dilakukan untuk mengurangi rasa nyeri, diantaranya dengan menggunakan metode farmakologis. Namun sayangnya metode ini hampir semua mempunyai efek samping pada ibu dan juga pada janin. Karena itu diperlukan tindakan non farmakologis yang sebagian besar bersifat distraksi tidak menyebabkan efeksamping baik pada ibu dan janin.

The objective of the present study was to evaluate the efficiency and safety of the treatment of girls presenting with Turner syndrome by recombinant growth hormone Rastan (Farmstandart-UfaVITA). A total 29 girls in this condition were available for observation. Their chronological age at the time of diagnosis averaged 7.9±1.2 years at the time of diagnosis and 9.8±1.6 at the onset of therapy; the bone age was 7.5±1.1 years. Duration of the treatment was 24 months. Recombinant somatotropin was used in the form of lyophilisate (1.33 mg) to prepare a solution for subcutaneous injections at a dose of 0.05 mg/kg of body weight. The solution was administered daily at evening hours. The mean growth rate of the patients with Turner syndrome was estimated at 4.2±0.6 cm/year prior to Rastan therapy, 8.7±0.6 cm/year during the first 12 months of the treatment, and 6.1±1.2 cm/yr in the second year. Overall, the height of the girls increased by 0.84 SD within the two years. No adverse effects of therapy were documented. It is concluded that the use of recombinant somatotropin Rastan is an efficacious and safe therapeutic modality for the acceleration of growth in girls with Turner syndrome.

Pain is the most dominan the first stage of childbirth. Pain of labor it can cause stress that causes, so it causing the release of hormone much like katekolamin and steroids. Excessive hormone secretion will cause Impaired uteroplacental circulation Thus causing hypoxia in the fetus. One for controlling labor pain by non-pharmacological methods that is warm compress Objective: to know The influence of warm compressesto pain in the first stage of the active phase Independent midwives cirebon city Methods: This research method Using design quasy eksprerimen design pre and post one group design The study sample is first stage of childbirth in independent midwifes city cirebon As many thirty respondents The data used in this study is the primary data Primary using a questionnaire given directly to the respondent. Stages of data analysis used are univariate and bivariate. Results: The result of the analysis shows the value of coefficient Z of 4,820 and Asym.Sig (p value) of 0.000. This shows that the value of Asym.Sig (p value)

Hormon rasta ima ključnu ulogu u mnogim fiziološkim procesima, anabolički efekti, stimulisanje rasta dugih kostiju, regulacija transkripcije gena u ciljnim ćelijama su uglavnom posredovani preko mitogenog polipeptida, insulinu sličan faktor rasta tip 1 (insulin like growth factor 1-IGF-1). Hormon rasta indukuje proizvodnju IGF-1 u jetri, koji reaguje sa receptorima ciljnih organa indukujući rast, odnosno IGF-1 posreduje svim stimulativnim dejstvima hormona rasta na kost, hrskavicu, rast mišić a i na metabolizam masti i ugljenih hidrata. U proceni redovnosti, bezbednosti i efikasnosti terapije hormonom rasta koristi se merenje koncentracije IGF-1 u serumu. Istraživanje je urađeno kao retrospektivno-prospektivna studija, a obuhvatilo je 80 pacijenata na terapiji hormonom rasta koja se kontrolišu i leče na Odeljenju za endokrinologiju, dijabetes i bolesti metabolizma Instituta za zdravstvenu zaštitu dece i omladine Vojvodine u Novom Sadu. Istraživani uzorak je obuhvatio 80 pacijenata, od kojih 35 dece sa nedostatkom hormona rasta, 24 dece rođene male za gestacionu dob i 21 devojčicu sa Tarnerovim sindromom. Svi ispitanici su praćeni od početka primene hormona rasta i tokom prve dve godine terapije hormonom rasta. U ovom istraživanju su praćeni auksološki i laboratorijski parametri u cilju ispitivanja odgovora na terapiju hormonom rasta. Praćene su bazalne vrednosti IGF-1 i promene nivoa IGF-1 u serumu tokom terapije hormonom rasta i korišćene da bi se ispitao odgovor na terapiju hormonom rasta, praćenjem brzine rasta, promena skora standardnih devijacija - SSD za telesnu visinu i koštanog sazrevanja. Ciljevi istraživanja su bili da se utvrdi povezanost vrednosti insulinu sličnog faktora rasta tip 1, brzine rasta i koštanog sazrevanja tokom terapije hormonom rasta. Takođe je poređena brzina rasta dece sa deficitom hormona rasta, devojčica sa T arnerovim sindromom i dece rođene male za gestaciono doba na terapiji hormonom rasta. U istraživanom uzorku, dvogodišnjim praćenjem terapije hormonom rasta je postignut dobar odgovor na terapiju, među decom sa nedostatkom hormona rasta je 71,5% postiglo normalnu telesnu visinu (±2 SSDTV) posle dve godine terapije hormonom rasta, 79,2% dece rođene male za gestacionu dob i 42,9% devojčica sa Tarnerovim sindromom. Značajna zastupljenost dece prepubertetskog uzrasta na početku terapije hormonom rasta, među decom sa nedostatkom hormona rasta 77,2%, među decom rođenom malom za gestacionu dob 79,1% i među devojčicama sa Tarnerovim sindromom 90,5% što je značajno uticalo na uspešnost terapije. Tokom terapije hormonom rasta je utvrđeno povećanje brzine rasta i SSD TV kod sve tri grupe ispitanika. U sve tri grupe ispitanika je tokom terapije hormonom rasta utvrđen porast nivoa IGF-1 seruma i SSDIGF-1 i ubrzanje koštanog sazrevanja tokom terapije hormonom rasta. Za prvih šest meseci terapije nema statistički značajnih razlika među grupama u brzini rasta (p>0,05), dok je za period prve i druge godine terapije hormonom rasta utvrđeno da postoji statistički značajna razlika među grupama (p<0,05), da je brzina rasta kod devojčica za Tarnerovim sindromom statistički značajno manja i od brzine rasta kod dece sa nedostatkom hormona rasta (p <0,05), i od brzine rasta kod dece rođene male za gestacionu dob (p<0,05). Među decom sa nedostatkom hormona rasta i dece rođene male za gestacionu dob nema statistički značajne razlike u brzini rasta (p>0,5). U ovom istraživanju je praćenjem auskoloških i laboratrijskih parametara tokom dvogodišnje primene hormona rasta, konstruisano više matematičkih modela za predviđanje odgovora na terapiju hormona rasta koji su statistički veoma značajani sa visokim koeficijentom višestruke linearne korelacije. U ovom istraživanju nije dobijena statistički značajna korelacija izmedju nivoa promene IGF-1 i brzine rasta za ceo uzorak, kao ni za decu sa nedostatkom hormona rasta, decu rođenu malu za gestacionu dob i devojčice za Tarnerovim sindromom. Nije dobijena statistički značajna korelacija izmedju nivoa promene IGF-1 i ubrzanja koštanog sazrevanja za ceo uzorak i za tri grupe pacijenata.
Growth hormone plays a key role in many physiological processes. The anabolic effects, the stimulation of growth of the long bones and the regulation of gene transcription in the target cells are mediated mainly via mitogenic polypeptide and insulin-like growth factor type 1 (insulin like growth factor 1-IGF-1). Growth hormone induces the production of IGF-1 in the liver, which interacts with receptors of the target organs inducing growth, that is, IGF-1 mediates all the stimulating effects of growth hormone on bone, cartilage, muscle growth and the metabolism of fats and carbohydrates. In assessing the regularity, safety and efficacy of growth hormone therapy, measuring the concentration of IGF-1 in serum is used. The survey was conducted as a retrospective-prospective study and involved 80 patients treated with growth hormone, monitored and treated at the Department of Endocrinology, Diabetes and Metabolic Diseases, at the Institute for Health Protection of Children and Youth of Vojvodina in Novi Sad. Investigated sample included 80 patients, of whom 35 children have growth hormone deficiency, 24 children were born small for gestational age and 21 girls with Turner syndrome. All the patients were monitored from the beginning of the administration of growth hormone and during the first two years of growth hormone therapy. In this study, auxological and laboratory parameters were monitored for the purpose of examining the response to treatment of growth hormone. The basal values of IGF-1 and changes in IGF-1 levels in serum, along with monitoring the rate of growth velocity and recent changes in standard deviation - SSD for body height and bone maturation, were monitored during growth hormone therapy and used for the evaluation of the response to growth hormone therapy. The objectives of the study were to determine the correlation of insulin-like growth factor type 1 values, the growth velocity and maturation of bone during growth hormone therapy. Also, the growth velocity in children with growth hormone deficiency was compared with the growth velocity in girls with Turner syndrome and in children born small for gestational age while treated with growth hormone. Two-year monitoring of growth hormone therapy in the study sample has show n good response to therapy. 71.5% of children with growth hormone deficiency, 79.2% of children born small for gestational age, and 42.9% of girls with Turner syndrome achieved normal body height (± 2 SSDTV) after two years of growth hormone therapy. There was a significant share of children at prepubertal age at the beginning of growth hormone therapy: 77.2% of children with growth hormone deficiency, 79.1% of children born small for gestational age and 90.5% of girls with Turner syndrome, which significantly influenced the success of the therapy. During the growth hormone therapy there was an increase of growth velocity and SSD TV in all three groups of children. An increase in levels of IGF-1 serum and SSDIGF-1 and acceleration of bone maturation were determined in all three groups of patients during growth hormone therapy. For the first six months of therapy there was no statistically significant difference between groups in growth velocity (p> 0.05), while the period of the first and second year of growth hormone therapy showed a statistically significant difference between groups (p <0.05). The growth velocity in girls with Turner syndrome was significantly lower than the growth velocity in children with growth hormone deficiency (p <0.05) and in children born small for gestational age (p <0.05). Between children with growth hormone deficiency and children born small for gestational age there was no statistically significant difference in growth velocity (p> 0.5). By monitoring auxological and laboratory parameters during the two years of application of growth hormone, several highly statistically significant mathematical models for predicting the response to treatment of growth hormone were constructed in this study with a high coefficient of multiple linear correlation. In this study, there was no statistically significant correlation between the level of change in IGF-1 and growth velocity for the entire sample, as well as for children with growth hormone deficiency, children born small for gestational age and girls for Turner syndrome. There was no statistically significant correlation between the level of change in IGF-1 and acceleration of bone maturation for the entire sample and for the three groups of patients.

El objetivo principal de esta tesis es caracterizar los efectos de las hormonas sexuales sobre la función mitocondrial del tejido adiposo blanco (TAB) y del músculo, y su relación con la síntesis de adiponectina. Nuestros resultados establecen el 17beta-estradiol como estimulador de la funcionalidad mitocondrial y de la síntesis de adiponectina en adipocitos y músculo, mientras que la testosterona actúa como un elemento negativo sobre los mismos procesos en los adipocitos. Asimismo, se ha estudiado el dimorfismo sexual en la modulación de los efectos de la rosiglitazona en el TAB de ratas intolerantes a la glucosa, poniendo de manifiesto que el TAB gonadal de las hembras es más sensible a los efectos de la rosiglitazona que el de los machos. En conjunto, los resultados apoyan la existencia de una conexión entre función mitocondrial y síntesis de adiponectina en TAB y en músculo que estaría modulada por las hormonas sexuales.

This chapter tests the limits of understanding what masculinity means or tries to mean. It insists that queer masculinities are those that are not only suspicious, resistant, or out of the ordinary, but are also those that elude while stabilizing meaning. In other words, at the moment we examine the Rocky Horror Picture Show or an online dating site, we establish a set of assumptions regarding who people are; yet, we develop this interplay of subjectivities that presumptively iterates binaries without ever challenging how heterosexuality is nothing more than a construction of the masculine ideal. The chapter beckons us to not get too comfortable with our learned sense that we know what masculinity is. It turns our assumptions regarding masculinity topsy-turvy and forces us to recognize that whether you are a Rasta, rude boy, martial artist, womanizer, athlete, or soldier, masculinities are defined social constructions that vary across culture, context, and community.